Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Alnylam Pharmaceuticals, Inc. (ALNY) had Normalized Income after Taxes of $164.49M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$1.29B |
|
$164.49M |
|
$298.45M |
|
$992.50M |
|
$1.06B |
|
$231.44M |
|
$-53.63M |
|
$177.81M |
|
$177.81M |
|
$164.49M |
|
$164.49M |
|
$164.49M |
|
|
Normalized Income after Taxes |
$164.49M |
$231.44M |
|
$245.34M |
|
133.61M |
|
138.28M |
|
$1.23 |
|
$1.21 |
|
| Balance Sheet Financials | |
$4.62B |
|
$554.14M |
|
$938.60M |
|
$5.56B |
|
$1.51B |
|
$1.01B |
|
$2.69B |
|
$4.20B |
|
$1.35B |
|
$1.35B |
|
$1.35B |
|
133.73M |
|
| Cash Flow Statement Financials | |
$397.23M |
|
$-389.00M |
|
$51.95M |
|
$1.66B |
|
$1.71B |
|
$50.67M |
|
$156.78M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.05 |
|
-- |
|
-- |
|
0.43 |
|
0.75 |
|
76.88% |
|
17.93% |
|
17.93% |
|
-- |
|
13.77% |
|
12.74% |
|
$340.71M |
|
-- |
|
-- |
|
-- |
|
0.23 |
|
3.07 |
|
1.41 |
|
63.63 |
|
12.15% |
|
12.15% |
|
2.96% |
|
6.96% |
|
$10.13 |
|
$2.46 |
|
$2.87 |
|